Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04174612

AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance — AMELIORATE  

Acute Myeloid Leukemia With FLT3/ITD Mutation Clinical Trial

Official title:
A Phase 3, Prospective, Randomized Multi-center Intervention Trial of Early Intensification in AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance: A MYNERVA-GIMEMA Study

Clinical Trial Summary

Prospective, multi-center, interventional, randomized, open clinical trial for the treatment of acute myeloid leukemia with FLT3 mutations customized upon the prognostic parameter PBC

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Acute Myeloid Leukemia With FLT3/ITD Mutation
Clinical Trial Details
NCT number NCT04174612
Study type Interventional
Source Gruppo Italiano Malattie EMatologiche dell'Adulto
Contact Paola Fazi
Phone 0670390528
Email p.fazi@gimema.it
Status Recruiting
Phase Phase 3
Start date April 24, 2020
Completion date August 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05596968 - The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
Recruiting NCT05596981 - The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
Terminated NCT01028716 - Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Not yet recruiting NCT05876832 - A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) Phase 3
Completed NCT03735875 - Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT01578109 - Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Phase 1
Completed NCT04788420 - Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML
Recruiting NCT06222580 - SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Phase 1
Active, not recruiting NCT03333486 - Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Phase 2
Terminated NCT02634827 - Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation Phase 2
Completed NCT01760655 - Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Phase 2
Recruiting NCT05024552 - Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML Phase 1
Completed NCT01253070 - Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Phase 2